title: Statins may reduce femoral osteolysis in patients with total Hip arthroplasty.
abstract: In experimental studies, statin use has been associated with reduction of osteoclastic activity and promotion of bone formation around implants. Moreover, a large clinical study recently reported a substantially reduced risk of revision for aseptic loosening among statin users with THA. Our objective was to evaluate the influence of statin use on the development of femoral osteolysis within 5 years after THA. We conducted a case-cohort study including all THAs presenting with femoral osteolysis at the 5 year visit (cases) and compared them with those without osteolysis (controls). Cases and controls were identified from a cohort of primary THAs operated between 2001 and 2005. Seven hundred thirty-five THAs were included, mean age 68 years. Five years after surgery osteolysis had developed around the femoral component of 40 THAs (5.4%). Ever-use of statins was much less frequent among cases (5 of 40, 12.5%) than among controls (199 of 695, 28.6%). The crude risk ratio of femoral osteolysis among statin users was 0.36 (95% CI 0.14; 0.92). After adjusting for age, sex, activity level, BMI, diagnosis, bearing surface, and type of stem, the adjusted risk ratio was 0.38 (95% CI 0.15; 0.99). In conclusion, statin use was associated with a reduced risk of developing femoral osteolysis 5 years after THA. Statins may be useful for reducing the risk of implant failure following THA.
authors.affiliation: Division of Orthopaedics and Trauma Surgery, Geneva University Hospitals, 4, rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. anne.lubbekewolff@hcuge.ch
authors.forename: Anne
authors.initials: A
authors.lastname: Lübbeke
authors.forename: Guido
authors.initials: G
authors.lastname: Garavaglia
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Rothman
authors.forename: Alexis
authors.initials: A
authors.lastname: Bonvin
authors.forename: Constantinos
authors.initials: C
authors.lastname: Roussos
authors.forename: Hermes
authors.initials: H
authors.lastname: Miozzari
authors.forename: Pierre
authors.initials: P
authors.lastname: Hoffmeyer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip / Q000706:statistics & numerical data; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D005269:Femur / Q000187:drug effects / Q000601:surgery; D006621:Hip Joint / Q000187:drug effects / Q000601:surgery; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010014:Osteolysis / Q000188:drug therapy* / Q000453:epidemiology; D011183:Postoperative Complications / Q000188:drug therapy* / Q000453:epidemiology; D011475:Prosthesis Failure / Q000187:drug effects*; D012042:Registries; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors